Merck & Co., Inc. $MRK Shares Acquired by BlackRock Inc.

Key Points

• BlackRock increased its Merck stake by 0.5% in the second quarter, adding 1.07 million shares to hold nearly 227 million shares worth $29.17 billion, or 9.19% of the company. Institutional investors collectively own 76.07% of Merck.
• Merck’s shares recently rallied 3.9% to $156.54, supported by positive cancer-vaccine trial results and increasingly bullish analyst forecasts. The stock has a “Moderate Buy” consensus rating and a $147.60 average price target, though its current price is above that target.
• Key risks include elevated expectations and insider selling: executives sold roughly 228,000 shares worth $30 million over the past 90 days, while future gains depend on successful pipeline trials, regulatory decisions and growth beyond KEYTRUDA.

BlackRock Inc. increased its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 0.5% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 226,999,837 shares of the company's stock after purchasing an additional 1,073,507 shares during the period. BlackRock Inc. owned 9.19% of Merck & Co., Inc. worth $29,169,479,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cascade Financial Partners LLC raised its position in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company's stock valued at $1,895,000 after acquiring an additional 80 shares in the last quarter. Somerset Trust Co lifted its position in Merck & Co., Inc. by 0.9% in the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company's stock valued at $1,118,000 after purchasing an additional 81 shares during the last quarter. Stonebridge Financial Group LLC boosted its stake in Merck & Co., Inc. by 0.9% during the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company's stock valued at $1,124,000 after purchasing an additional 81 shares during the period. Stronghold Wealth Management L.L.C. grew its position in Merck & Co., Inc. by 2.6% in the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company's stock worth $416,000 after purchasing an additional 82 shares during the last quarter. Finally, Lederer & Associates Investment Counsel CA grew its position in Merck & Co., Inc. by 0.9% in the 2nd quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company's stock worth $1,234,000 after purchasing an additional 84 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive topline INTerpath-001 results strengthened expectations that the vaccine could extend KEYTRUDA’s growth runway and create a potentially important new oncology franchise. Merck Surges on a Melanoma Win
• Positive Sentiment: Analysts raised their valuation expectations: Wolfe Research increased its price target to $180 and assigned an “outperform” rating, while Argus raised its target to $170 and reiterated a “buy” rating. Wolfe Research Price Target
• Positive Sentiment: Investors are also anticipating a concentrated series of regulatory decisions and clinical readouts this fall, which could produce additional upside if Merck’s pipeline delivers. What Would It Take to Get MRK Stock to $200?
• Neutral Sentiment: The cancer-vaccine opportunity remains early. The available evidence is limited, and potential barriers include manufacturing complexity, cost, patient selection, and the need for regulatory review and broader clinical validation. How the Merck/Moderna Cancer Vaccine Works
• Negative Sentiment: After the recent rally, MRK is trading near or above several analysts’ prior targets, leaving less room for disappointment and making future gains increasingly dependent on successful trial results, FDA decisions, and evidence that the post-KEYTRUDA growth strategy can scale.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Daiwa Securities Group upgraded Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price objective for the company in a research report on Wednesday, August 12th. JPMorgan Chase & Co. raised their target price on Merck & Co., Inc. from $135.00 to $140.00 and gave the company an "overweight" rating in a research report on Monday, July 13th. Bank of America lifted their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a research note on Tuesday, June 30th. Morgan Stanley raised Merck & Co., Inc. from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $116.00 to $179.00 in a research note on Thursday, August 20th. Finally, Argus raised their price target on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a "buy" rating in a report on Tuesday. Fifteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $147.60.

Insider Activity

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares of the company's stock, valued at $6,073,631.14. The trade was a 63.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of the company's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the transaction, the executive vice president owned 18,212 shares in the company, valued at $2,344,248.64. This represents a 50.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 228,238 shares of company stock valued at $29,977,783 in the last ninety days. Corporate insiders own 0.17% of the company's stock.

Merck & Co., Inc. Trading Up 3.9%

Shares of NYSE:MRK opened at $156.54 on Wednesday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The stock has a market capitalization of $386.22 billion, a price-to-earnings ratio of 125.23, a PEG ratio of 6.32 and a beta of 0.19. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $156.92. The company has a 50 day moving average price of $129.64 and a 200 day moving average price of $121.80.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company had revenue of $16.61 billion for the quarter, compared to analysts' expectations of $16.37 billion. During the same quarter in the prior year, the company earned $2.13 earnings per share. The firm's revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.'s payout ratio is presently 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source